Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary EndpointsBenzinga • 02/14/22
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South KoreaPRNewsWire • 02/14/22
FDA plan to fast-track Pfizer vaccine for kids under 5 fails to deliver, leaving parents waiting until AprilCNBC • 02/12/22
Pfizer pauses request for FDA authorization of COVID vaccines for kids under 5, awaits more trial dataFox Business • 02/11/22
Pfizer has pulled its FDA request to authorize a 2-dose shot for kids under 5, saying it will 'wait for the 3-dose data'Business Insider • 02/11/22
Pfizer, BioNTech to delay seeking authorization of their COVID-19 shot in young childrenMarket Watch • 02/11/22
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of AgeBusiness Wire • 02/11/22
Earnings Results: Pfizer expects a record $100 billion in revenue this year, thanks to COVID vaccines and treatmentsMarket Watch • 02/08/22
Pfizer Inc. (PFE) CEO Albert Bourla on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/08/22